![]() |
Name |
3,4,7-Trimethylisoquinoline-6,8-diol
|
Molecular Formula | C12H13NO2 | |
IUPAC Name* |
3,4,7-trimethylisoquinoline-6,8-diol
|
|
SMILES |
CC1=C(N=CC2=C(C(=C(C=C12)O)C)O)C
|
|
InChI |
InChI=1S/C12H13NO2/c1-6-8(3)13-5-10-9(6)4-11(14)7(2)12(10)15/h4-5,14-15H,1-3H3
|
|
InChIKey |
SKBAWFZTQMWMSY-UHFFFAOYSA-N
|
|
Synonyms |
3,4,7-trimethylisoquinoline-6,8-diol
|
|
CAS | NA | |
PubChem CID | 155803974 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 203.24 | ALogp: | 2.5 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 53.4 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.69 |
Caco-2 Permeability: | -4.738 | MDCK Permeability: | 0.00001530 |
Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.07 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.915 |
30% Bioavailability (F30%): | 0.971 |
Blood-Brain-Barrier Penetration (BBB): | 0.183 | Plasma Protein Binding (PPB): | 94.98% |
Volume Distribution (VD): | 0.744 | Fu: | 4.20% |
CYP1A2-inhibitor: | 0.962 | CYP1A2-substrate: | 0.945 |
CYP2C19-inhibitor: | 0.049 | CYP2C19-substrate: | 0.434 |
CYP2C9-inhibitor: | 0.047 | CYP2C9-substrate: | 0.578 |
CYP2D6-inhibitor: | 0.177 | CYP2D6-substrate: | 0.809 |
CYP3A4-inhibitor: | 0.095 | CYP3A4-substrate: | 0.252 |
Clearance (CL): | 12.68 | Half-life (T1/2): | 0.664 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.199 |
Drug-inuced Liver Injury (DILI): | 0.895 | AMES Toxicity: | 0.361 |
Rat Oral Acute Toxicity: | 0.422 | Maximum Recommended Daily Dose: | 0.754 |
Skin Sensitization: | 0.924 | Carcinogencity: | 0.436 |
Eye Corrosion: | 0.023 | Eye Irritation: | 0.937 |
Respiratory Toxicity: | 0.821 |